Foamix Pharmaceuticals Announces Upsizing and Pricing of Its Public Offering

Foamix Pharmaceuticals Ltd. (Nasdaq:FOMX), a specialty pharmaceutical company focused on developing topical foams to address unmet needs in dermatology, today announced the pricing of an upsized public offering of 6,451,612 ordinary shares at a price to the public of $9.30 per share. In addition, Foamix has granted the underwriters a 30-day option to purchase up to 967,741 additional ordinary shares. The offering is expected to close on Monday, April 20, 2015, subject to customary closing conditions.